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MoBACKGROUND Genome-wide association studies have so far identiﬁed 56 loci associated with risk of coronary artery
disease (CAD). Many CAD loci show pleiotropy; that is, they are also associated with other diseases or traits.
OBJECTIVES This study sought to systematically test if genetic variants identiﬁed for non-CAD diseases/traits also
associate with CAD and to undertake a comprehensive analysis of the extent of pleiotropy of all CAD loci.
METHODS In discovery analyses involving 42,335 CAD cases and 78,240 control subjects we tested the association of
29,383 common (minor allele frequency >5%) single nucleotide polymorphisms available on the exome array, which
included a substantial proportion of known or suspected single nucleotide polymorphisms associated with common
diseases or traits as of 2011. Suggestive association signals were replicated in an additional 30,533 cases and 42,530
control subjects. To evaluate pleiotropy, we tested CAD loci for association with cardiovascular risk factors (lipid traits,
blood pressure phenotypes, body mass index, diabetes, and smoking behavior), as well as with other diseases/traits
through interrogation of currently available genome-wide association study catalogs.
RESULTS We identiﬁed 6 new loci associated with CAD at genome-wide signiﬁcance: on 2q37 (KCNJ13-GIGYF2), 6p21
(C2), 11p15 (MRVI1-CTR9), 12q13 (LRP1), 12q24 (SCARB1), and 16q13 (CETP). Risk allele frequencies ranged from 0.15 to
0.86, and odds ratio per copy of the risk allele ranged from 1.04 to 1.09. Of 62 new and known CAD loci, 24 (38.7%)
showed statistical association with a traditional cardiovascular risk factor, with some showing multiple associations, and
29 (47%) showed associations at p < 1  104 with a range of other diseases/traits.
CONCLUSIONS We identiﬁed 6 loci associated with CAD at genome-wide signiﬁcance. Several CAD loci show
substantial pleiotropy, which may help us understand the mechanisms by which these loci affect CAD risk.
(J Am Coll Cardiol 2017;69:823–36) © 2017 The Authors. Published by Elsevier on behalf of the American College of
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827ascertained to have no sample overlap with the dis-
covery cohorts, included 30,533 cases and 42,530
control subjects from 8 studies (Online Table 2). With
the exception of participants from 2 studies in the
replication cohort who were of South Asian ancestry,
all participants were of European ancestry (Online
Table 2).
Samples were genotyped on the Illumina
HumanExome BeadChip versions 1.0 or 1.1, or the
Illumina OmniExome (which includes markers from
the HumanExome BeadChip) arrays followed by
quality control procedures as previously described (5).
STATISTICAL ANALYSIS. In discovery samples that
passed quality control procedures, we performed in-
dividual tests for association of the selected variants
with CAD in each study separately, using logistic
regression analysis with principal components of
ancestry as covariates (5). We combined evidence
across individual studies using an inverse-variance
weighted ﬁxed-effects meta-analysis. Heterogeneity
was assessed by Cochran’s Q statistic (6). In the dis-
covery phase, we deﬁned suggestive novel associa-
tion as a meta-analysis p value #1  106.
For variants with suggestive association, we
performed association analysis in the replication
studies (Online Appendix). We deﬁned signiﬁcant
novel associations as those nominally signiﬁcant
(p < 0.05) in the replication study and with an
overall (discovery and replication combined)
p value <5  108.
BIOINFORMATICS ANALYSIS. To identify any asso-
ciation between the novel loci and gene expression
traits, we performed a systematic search of cis-
expression quantitative trait loci (eQTL) (described
in the Online Appendix). To identify candidate causal
SNPs at the new loci, we annotated each of the lead
variants as well as SNPs in high linkage disequilib-
rium (LD) (r2 > 0.8) on the basis of position, overlap
with regulatory elements, and in silico SNP prioriti-
zation tools (Online Appendix).
For both the novel loci and all previously reported
CAD loci (1,2), we tested the association of the lead
CAD-associated variant (or, if unavailable, a proxy)
with traditional cardiovascular risk factors using
publicly available GWAS meta-analyses datasets for
systolic, diastolic, and pulse pressures (7,8); low-
density lipoprotein (LDL) cholesterol level; high-
density lipoprotein (HDL) cholesterol level; tri-
glycerides level (9,10); type 2 diabetes mellitus (11);
body mass index (BMI) (12); and smoking quantity
(13). The maximum size of these datasets ranged from
41,150 to 339,224 individuals. For variants availableon the exome array with a known genome-wide as-
sociation with a risk factor, we also compared the
magnitude of the reported association with the risk
factor to the observed association with CAD in our
analysis.
To identify any associations with other diseases or
traits, we searched version 2 of the GRASP (Genome-
Wide Repository of Associations between SNPs and
Phenotypes) database (14) and the National Human
Genome Research Institute-European Bioinformatics
Institute GWAS catalog (15), plus we collected all as-
sociations below 1  104. For all associations, we
identiﬁed the lead variant for that trait or disease and
calculated pairwise LD with the lead CAD-associated
variant using the SNAP web server (16).
RESULTS
In the discovery cohort, 28 variants not located in a
known CAD locus (deﬁned as 300 kb from the pub-
lished lead SNP) showed association with CAD at a
p value <1  106 (Online Table 3). No marked het-
erogeneity was observed, justifying the use of a ﬁxed-
effects model. We then tested these 28 variants for
replication, and 6 variants showed both a nominally
signiﬁcant (p < 0.05) association in the replication
cohort and a combined discovery and replication
meta-analyses p value exceeding the threshold for
genome-wide signiﬁcance (p < 5  108) (Table 1). As
typical for GWAS ﬁndings, the risk alleles were com-
mon (allele frequencies ranging from 15% to 86%),
and the risk increase per allele was modest (ranging
from 4% to 9%) (Table 1).
ANNOTATION OF NOVEL LOCI. Forest and regional
association plots for the 6 novel loci are shown in
Online Figures 1 and 2, respectively. Interrogation of
the 1000 Genomes Project phase 1 EUR data using
Haploreg (BROAD Institute, Massachusetts Institute
of Technology and Harvard, Boston, Massachusetts)
(17) showed that the number of SNPs in high LD
(r2 > 0.8) with the lead variant varied between 1 (LRP1
locus and CETP locus) and 111 (KCNJ13-GIGYF2 locus)
(Online Table 4). Apart from the lead variant at the
KCNJ13-GIGYF2 locus, which is a nonsynonymous
SNP, none of the other loci had a variant affecting
protein sequence in high LD with the lead variant.
Notable cis-eQTL ﬁndings for the new loci are
shown in Online Table 5 and functional annotation of
the lead variant and variants in high LD appear in
Online Figure 3. The main ﬁndings from these ana-
lyses are discussed here locus by locus.
16q13 . The lead variant, rs1800775, also known
as 629C>A, is in the promoter of the cholesteryl
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828ester transfer protein (CETP) gene, which mediates
the transfer of cholesteryl esters from HDL choles-
terol to other lipoproteins and was placed on the
array because of its association with plasma HDL
cholesterol level (9,10). The risk (C) allele is associ-
ated with lower HDL cholesterol and modest in-
creases in plasma LDL cholesterol and triglycerides
levels (9,10). Previous studies have shown that
rs1800775 is itself functional in that the C allele dis-
rupts binding of the Sp1 transcription factor resulting
in increased promoter activity (18). This is in agree-
ment with our annotation, which predicts this to be
more likely to be a functional SNP than the only other
SNP in high LD, rs3816117 (Online Figure 3). Consis-
tent with this, we also found associations between
rs1800775 and CETP expression (r2 of 0.77) with the
best eSNP (i.e., the lead SNP for the eQTL) in mono-
cytes and liver (Online Table 5), and previous studies
have shown that the variant is also associated with
plasma CETP level (19,20).
12q24. The lead variant, rs11057830, and all 8 vari-
ants in high LD are located in a region of approxi-
mately 10 kb in intron 1 of SCARB1, which encodes SR-
B1, a receptor for HDL cholesterol. Other variants at
this locus have been associated with HDL cholesterol
level (9,10). However, these HDL cholesterol variants
are not in high LD with the CAD-associated variants
identiﬁed here, which only have a modest association
with plasma HDL cholesterol level (Online Table 6),
but a stronger association with plasma LDL choles-
terol and triglycerides levels (Table 2). rs11957830 was
included on the array because of an association of the
A allele (CAD risk-associated allele) with higher levels
of vitamin E (Table 3) (21). Variants in high LD with
the CAD risk allele at rs11057830 have also been
associated with increased lipoprotein-associated
phospholipase A2 (Lp-PLA2) activity (22). Analysis of
eQTL identiﬁed an association between rs11057841
(r2 ¼ 0.92 with the lead variant), and expression of
SCARB1 in the intestine (Online Table 5). Functional
annotation of the locus did not identify a strong
candidate causal SNP, but rs10846744 (r2 ¼ 0.94 with
the lead variant) overlaps a deoxyribonuclease I hy-
persensitivity peak in a region bound by several
transcription factors (Online Figure 3).
12q13 . The lead variant, rs11172113, is in intron 1 of
LRP1 (LDL receptor–related protein-1) and only has 1
other adjacent SNP in high LD (Central Illustration,
Online Table 4). The risk (C) allele of the lead variant
has previously been associated with reduced risk of
migraine (23), and there is an association of the
alternate (T) allele with reduced lung function (24).
There are also associations at this locus for abdominal
aortic aneurysm (25) and triglyceride levels (10);
TABLE 2 Signiﬁcant Associations of CAD Variants With Selected CV Risk Factors*
Locus Locus Name Lead Variant Trait Effect p Value
New Loci
6p21 C2 rs3130683 T2D 1.12† 2.7  105
SCARB1 rs11057830 LDL 0.006 2.6  105
TG 0.022 8.3  105
16q13 CETP rs1800775 LDL 0.041 8.5  1024
HDL 0.202 3.3  10644
TG 0.04 1.3  1026
Known Loci
1p32 PCSK9 rs11206510 LDL 0.083 2.4  1053
1p13 SORT1 rs602633 LDL 0.159 1.5  10261
HDL 0.033 3.5  1014
2p24 APOB rs515135 LDL 0.139 1.1  10178
2p21 ABCG5-ABCG8 rs6544713 LDL 0.081 4.84  1083
4q32 GUCY1A3 rs7692387 DBP 0.326 3.4  105
5q31 SLC22A4-SLC22A5 rs273909 LDL 0.022 2.3  105
2q33 WDR12 rs6725887 LDL 0.026 1.3  105
6q25 LPA rs3798220 LDL 0.158 6.1  1011
rs2048327 LDL 0.019 1.3  106
7q32 ZC3HC1 rs11556924 DBP NA 1.8  105
HDL 0.018 1.3  105
7q36 NOS3 rs3918226 SBP 0.96 1.1  106
DBP 0.81 2.2  109
8p21 LPL rs264 HDL 0.098 8  1077
TG 0.093 2.4  1084
8q24 TRIB1 rs2954029 LDL 0.056 2.1  1050
HDL 0.04 2.7  1029
TG 0.076 1  10107
9q34 ABO rs579459 LDL 0.067 2.4  1044
10q24 CYP17A1-CNNM2-NT5C2 rs12413409 SBP 1.034 2  109
DBP 0.483 3.4  105
PP 0.56 5.7  108
BMI 0.03 2.2  108
11q23 ZNF259-APOA5-APOA1 rs964184 LDL 0.086 2  1026
HDL 0.107 6.1  1048
TG 0.234 6.6  10244
12q24 SH2B3 rs3184504 LDL 0.027 4.2  1012
HDL 0.026 4.1  1012
SBP 0.598 2  109
DBP 0.483 8.8  106
BMI 0.131 9.4  106
15q26 FURIN-FES rs17514846 SBP 0.509 1.2  105
17p13 SMG6 rs2281727 BMI 0.015 3.64  106
18q21 PMAIP1-MC4R rs663129 HDL 0.026 5.5  109
BMI 0.056 8.8  1053
19p13 LDLR rs1122608 LDL 0.074 8.5  1057
19q13 APOE-APOC1 rs2075650 LDL 0.177 1.7  10214
HDL 0.055 9.7  1026
TG 0.044 2.3  1021
BMI 0.026 1.3  108
rs445925 LDL 0.363 6.6  10397
HDL 0.051 1.9  1010
TG 0.101 3.6  1039
*Effects are either absolute beta estimates of the association of the CAD risk allele on the trait (with a positive
association indicating a higher value of the trait per copy of the risk allele) or log odds ratio for diabetes mellitus,
†per copy of the risk allele. This table only includes associations that passed Bonferroni correction.
BMI ¼ body mass index; CAD ¼ coronary artery disease; CV ¼ cardiovascular; DBP ¼ diastolic blood pressure;
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein cholesterol level; T2D ¼ type 2 diabetes mellitus;
TG ¼ triglycerides.
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829however, these variants are in modest or low LD to
the CAD-associated SNP (r2 of 0.54 and 0.07, respec-
tively). The lead variant overlaps a region containing
peaks in deoxyribonuclease I hypersensitivity in
several cells and tissues, including aortic smooth
muscle cells, within a predicted enhancer element
(Online Figure 3). We found associations between the
CAD risk allele at rs11172113 and reduced expression
of LRP1 in atherosclerotic and nonatherosclerotic
arterial wall, as well as eQTLs in omental and sub-
cutaneous adipose tissue (Online Table 5).
11p15 . The lead variant, rs11042937, at this locus lies
in an intergenic region between MRVI1 (murine
retrovirus integration site 1 homolog) encoding
inositol-trisphosphate receptor-associated cyclic
guanosine monophosphate kinase substrate, a medi-
ator of smooth muscle tone and CTR9 that encodes a
component of the PAF1 complex with some SNPs in
high LD located within intron 1 of MRVI1 (Online
Figure 3). The lead variant was included on the
array because of a suggestive association with bipolar
disorder and schizophrenia (26). There was no asso-
ciation of the locus with any cardiovascular risk fac-
tors, and we did not identify any eQTLs. Evidence for
a regulatory function for either the lead variant or any
of the SNPs in high LD was also weak (Online
Figure 3).
6p21 . The lead variant, rs3130683, lies in the HLA
complex in intron 1 of C2, which encodes the com-
plement C2 protein. There are just 14 SNPs in high LD
with the lead variant (Online Table 4), but the CAD
signal spans a region of approximately 300 kb
including more than 20 genes (Online Figure 3). Apart
from a single synonymous variant in HSPA1A (heat
shock 70kDa protein 1A), the other high LD variants
are noncoding with several of the variants showing
evidence for regulatory functionality (Online
Figure 3). Although there is a large number of eQTLs
in the HLA region, most of these are variants with
modest (r2 < 0.5) LD with the CAD-associated vari-
ants, and the only eQTL of note was with CYP21A2
(cytochrome P450, family 21, subfamily A, poly-
peptide 2) expression in whole blood (Online Table 5).
rs3869109, another variant at the HLA locus approx-
imately 700 kb away from the new lead variant, has
been reported to be associated with CAD (27). In our
discovery cohort, rs3869109 has a p value of associ-
ation with CAD of 0.23.
2q37 . The lead variant, rs1801251, was included on
the array for identity by descent testing; rs1801251
causes a threonine to isoleucine amino acid change
at position 95 in KCNJ13, an inwardly rectifying po-
tassium channel protein. However, this is not pre-
dicted to be functionally important. There is
TABLE 3 Association of CAD Loci With Other Diseases or Traits
Locus Locus Name Disease or Trait
Disease or Trait
Lead SNP p Value Direction
r2 (CAD Lead
and Disease
or Trait Lead)
New Loci
6p21 C2 Systemic lupus erythematosus rs3130342 9.3  107 þ 0.87
Primary biliary cirrhosis rs3134954 1  105 þ 0.86
Multiple sclerosis rs3134954 3.2  109  0.86
11p15 MRVI1-CTR9 Bipolar disorder and schizophrenia rs2018368 1  106 þ 0.96
12q13 LRP1 Migraine rs11172113 4.3  109  Same SNP
Lung function (FEV1/FVC) rs11172113 1.2  108 þ Same SNP
Cervical artery dissection rs11172113 3  107  Same SNP
12q24 SCARB1 Lp-PLA2 activity rs11057841 6.1  1014 þ 0.92
Circulating vitamin E levels rs11057830 8.2  109 þ Same SNP
Lp-PLA2 mass rs10846744 6.8  106 þ 0.94
Known Loci
1p32 SORT1 Lp-PLA2 activity rs7528419 1.3  1017 þ 0.9
Metabolic syndrome domains (Atherogenic
dyslipidemia–PC1)
rs12740374 8  1016 þ Same SNP
Lp-PLA2 mass rs7528419 7.1  105 þ 0.9
1q21 IL6R C-reactive protein rs4845625 4.2  107 þ Same SNP
2p21 ABCG5-ABCG8 Serum phytosterol rs4245791 2.2  1070 þ 1
2p11 VAMP5-VAMP8-GGCX Prostate cancer rs10187424 2.7  1015  0.87
2q33 WDR12 Cerebral white matter hyperintensities
burden
rs6705330 5.7  105 þ 1
3q22 MRAS Coronary artery calciﬁcation rs2306374 2.7  105 þ 1
4q12 REST-NOA1 Height rs17081935 6.7  1017 þ 0.95
4q31 EDNRA Carotid intima media thickness rs1878406 7  1012 þ Same SNP
Intracranial aneurysm rs6842241 2.4  109 þ 0.94
6p24 PHACTR1 Coronary artery calciﬁcation rs9349379 4  1022 þ Same SNP
Cervical artery dissection rs9349379 1  1011  Same SNP
Migraine rs9349379 5  108  Same SNP
Pulse wave velocity rs7750679 5.4  105 þ 1
6q25 LPA Lipoprotein (a) rs3798220 1.6  1049 þ Same SNP
Colorectal cancer rs7758229 5.6  109  0.85
7p21 HDAC9 Stroke (large vessel stroke) rs11984041 1.9  1011 þ 1
7q22 7q22 Endometriosis rs10953541 3.2  105 þ Same SNP
8q24 TRIB1 Metabolic syndrome domains (Atherogenic
dyslipidemia–PC1)
rs2954021 1.2  1011 þ Same SNP
Adiponectin levels rs2954021 1.8  105 þ Same SNP
Serum creatinine rs2954021 2.3  105 þ Same SNP
9p21 CDKN2BAS1 Coronary artery calciﬁcation rs1333049 3.3  1024 þ 0.97
Abdominal aortic aneurysm rs2383207 1.9  108 þ 0.91
Ankle brachial index rs10757269 2.7  109 þ 0.9
Stroke (large vessel stroke) rs2383207 2.4  106 þ 0.91
Intracranial aneurysm rs10733376 4  1012 þ 0.94
9q34 ABO Alkaline phosphatase in plasma rs579459 3  10123 þ Same SNP
Activated partial thromboplastin time rs579459 1.7  1074 þ Same SNP
Soluble P-selectin rs579459 1.9  1041 þ Same SNP
Soluble E-selectin rs579459 1.3  1029 þ Same SNP
Plasma carcinoembryonic levels rs579459 3  1021 þ Same SNP
Red blood cell count rs579459 9.3  1018 þ Same SNP
Hemoglobin rs579459 1.4  1015 þ Same SNP
Hematocrit rs579459 7.6  1014 þ Same SNP
Interleukin-6 levels rs579459 3.6  1013 þ Same SNP
Circulating galectin-3 levels rs579459 1.9  1010 þ Same SNP
Factor XIII antigen rs579459 2.3  108 þ Same SNP
von Willebrand factor rs651007 1  10161 þ 1
Venous thromboembolism rs495828 2  1017 þ 1
Continued on the next page
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TABLE 3 Continued
Known Loci
Serum alkaline phosphatase levels rs651007 1  1056 þ 1
Ferritin levels rs651007 1  108 þ 1
Soluble ICAM-1 rs507666 3  1091 þ 0.83
10q24 CYP17A1-CNNM2-
NT5C2
Intracranial aneurysm rs12413409 1.2  109 þ Same SNP
Schizophrenia rs11191580 1.7  109 þ 1
Autism spectrum disorder rs11191454 1.4  108 þ 1
Parkinson’s disease rs17115100 7.4  108 þ 0.9
11q23 ZNF259-APOA5-APOA1 Metabolic syndrome domains (Atherogenic
dyslipidemia–PC2)
rs964184 1.8  1012 þ Same SNP
Vitamin E levels rs964184 7.8  1012 þ Same SNP
Lp-PLA2 activity rs964184 8.4  1011 þ Same SNP
Metabolic syndrome domains (Atherogenic
dyslipidemia–PC1)
rs964184 1.2  1010 þ Same SNP
12q24 SH2B3 Selective immunoglobulin A deﬁciency rs3184504 5.6  1031 þ Same SNP
Type 1 diabetes rs3184504 2.8  1027 þ Same SNP
Celiac disease rs3184504 5.4  1021 þ Same SNP
Hemoglobin rs3184504 4.3  1019 þ Same SNP
Celiac disease rs3184504 5.4  1021 þ Same SNP
Blood eosinophil count rs3184504 6.5  1019 þ Same SNP
Generalized vitiligo rs3184504 2.5  1017 þ 0.97
Soluble ICAM-1 rs3184504 2.9  1017 þ Same SNP
Hematocrit rs3184504 7.9  1016 þ Same SNP
Hypothyroidism rs3184504 2.6  1012 þ Same SNP
Rheumatoid arthritis and celiac disease rs3184504 1.4  1011 þ Same SNP
Primary sclerosing cholangitis rs3184504 5.9  1011 þ Same SNP
Serum urate rs3184504 2.6  1010 þ Same SNP
Juvenile idiopathic arthritis rs3184504 2.6  109 þ 0.9
Lymphocyte count rs3184504 1.1  108 þ Same SNP
Plasma beta-2 microglobulin levels rs3184504 3.1  108 þ Same SNP
White blood cell count rs3184504 6.3  106 þ Same SNP
Rheumatoid arthritis rs3184504 6  106 þ Same SNP
Tetralogy of Fallot rs11065987 4.6  108 þ 0.91
13q34 COL4A1-COL4A2 Coronary artery calciﬁcation rs3809346 8.6  107 þ 0.97
15q22 SMAD3 Crohn’s disease rs17293632 2.7  1019  0.9
Inﬂammatory bowel disease rs17293632 6  1016  0.9
Ulcerative colitis rs17293632 9.5  106  0.9
Self-reported allergy rs17228058 1.2  108  0.9
15q25 ADAMTS7 Coronary artery calciﬁcation rs3825807 6.5  106 þ Same SNP
17p13 SMG6 Aortic root size rs10852932 2.3  1011 þ 0.96
17q21 UBE2Z Height rs318095 1.5  1016  1
Breast size (bra cup size in women) rs12603969 3  105  1
18q21 PMAIP1-MC4R Obesity rs17782313 4.8  1015 þ 0.86
Height rs11152213 6.9  1013 þ 0.91
Antipsychotic drug induced weight gain rs12967878 3.6  107 þ 0.9
19q13 APOE-APOC1 Common carotid artery intima-media
thickness
rs445925 1.7  108 þ Same SNP
Lp-PLA2 activity rs445925 3.3  1010 þ Same SNP
Metabolic syndrome domains (Atherogenic
dyslipidemia–PC1)
rs445925 1.3  1035 þ Same SNP
Alzheimer disease rs2075650 1  10295 þ Same SNP
Longevity rs2075650 3.4  1017  Same SNP
Lp-PLA2 activity rs2075650 8.1  1015 þ Same SNP
Age-related macular degeneration rs2075650 8.4  108  Same SNP
C-reactive protein rs2075650 4.2  108 þ Same SNP
Cognitive decline rs2075650 2  108 þ Same SNP
þ indicates increase in disease or trait with the CAD risk allele.
CAD ¼ coronary artery disease; FEV1 ¼ forced expiratory volume 1; FVC ¼ forced vital capacity; ICAM-1 ¼ intercellular adhesion molecule 1; Lp-PLA2 ¼ lipoprotein-associated phospholipase A2; PC ¼
principal component; SNP ¼ single nucleotide polymorphism.
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CENTRAL ILLUSTRATION Signiﬁcant Associations of CAD Loci With Cardiovascular Risk Factors
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This chord diagram depicts associations that passed Bonferroni correction (Table 2). Connections indicate that single nucleotide polymorphisms at
respective loci associate with both coronary artery disease (CAD) and the respective risk factor; they do not imply that the risk factor causally explains the
association with CAD. Red indicates new CAD loci. BMI ¼ body mass index; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein.
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832extended linkage at this locus, with more than 100
SNPs in high LD and the lead variant in a region of
w170 kb also spanning GIGYF2 (GRB10 interacting
GYF protein 2) (Online Figure 3). KCJN13 is located
entirely within GIGYF2 and transcribed in the oppo-
site direction. A number of the associated variants
are in annotated regulatory regions, with the topscoring candidate by in silico prediction, rs11555646,
lying in the 50-UTR of GIGYF2 close to the initiating
methionine (Online Figure 3). There was no associa-
tion of the locus with any of the cardiovascular risk
factors, but we found eQTLs for the lead variant or a
variant in high LD for both GIGFY2 and KCNJ13
(Online Table 5).
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833CAD LOCI AND PLEIOTROPY. We undertook an
updated analysis of the association of all 62 CAD loci
(56 published and 6 novel in this report) with tradi-
tional cardiovascular risk factors (blood pressure
traits, lipid traits, BMI, type 2 diabetes, and smoking).
The full results are shown in Online Table 6, and the
signiﬁcant associations are summarized in Table 2. Of
the 62 CAD loci, 24 (38.7%) showed a statistical as-
sociation at a Bonferroni corrected p value <8.32 
105 with a traditional cardiovascular risk factor with
some loci showing multiple associations (Central
Illustration). The largest number of associations
were with lipid traits (14 with LDL cholesterol, 9 with
HDL cholesterol, and 7 with triglycerides), followed
by blood pressure traits (5 with diastolic blood pres-
sure, 4 with systolic blood pressure, and 1 with pulse
pressure), BMI (5 associations), and type 2 diabetes
(1 association). Most associations were in the direc-
tion consistent from the epidemiological association
of these risk factors with CAD, although a few dis-
played effects in the opposite direction (the risk var-
iants at 2q33 and 12q24 are associated with reduced
plasma LDL cholesterol, and those at 10q24, 12q24,
and 19q13 are associated with lower BMI).
To inform the interpretation of these data, we
conducted a complementary analysis for variants
available on the array with a known genome-wide
association with a risk factor; also, we compared the
magnitude of the reported association with the risk
factor to the observed association with CAD in our
data. Except for LDL cholesterol and BMI, the corre-
lations between the 2 effects were either weak or
insigniﬁcant (Online Figure 4). In a separate analysis
conducted in the 150,000 participants in UK Biobank
with currently released genotype data, we conﬁrmed
that none of the CAD-associated variants showed a
sex difference in allele frequency (data not shown).
We next analyzed the association of the 62 CAD loci
with other diseases and traits. When restricted to
variants with a high LD (r2 > 0.8) with the lead CAD
variant, 29 of 62 (47%) loci showed an association
with another disease/trait at a p value <1  104.
Several loci showed multiple associations (Table 3).
Although in most cases, the CAD-associated risk allele
was also associated with an increased risk (or level) of
the other disease or trait, this was not always the
case. Furthermore, in some loci with multiple asso-
ciations, the direction of association varied between
diseases (Table 3).
DISCUSSION
This large-scale meta-analysis of common variants,
including many with prior evidence for associationwith another complex trait, resulted in the identiﬁ-
cation of 6 new CAD loci at genome-wide sig-
niﬁcance. We also showed that almost one-half of
the CAD loci that have been identiﬁed to date
demonstrate pleiotropy, an association with another
disease or trait. The ﬁndings added to our under-
standing of the genetic basis of CAD and might
provide clues to the mechanisms by which such loci
affect CAD risk.
Our ﬁndings of a genome-wide association with
CAD of a functional variant in the promoter of the
CETP gene that is also associated with its expression
and plasma activity (18–20) have added to previous
evidence linking genetically determined increased
activity of this gene with higher risk of CAD (20).
There has been a longstanding interest in CETP inhi-
bition as a therapeutic target, primarily because of the
effect on plasma HDL cholesterol level. However,
several CETP inhibitors have recently failed to
improve cardiovascular outcomes in large random-
ized clinical trials (28–30) and, in 1 case, caused harm
(28), despite markedly increasing plasma HDL
cholesterol. Furthermore, Mendelian randomization
studies have questioned the causal role of lower
plasma HDL cholesterol in increasing CAD risk (31,32).
Although previous studies have shown that the CETP
genetic variant we report here affects CETP activity,
the precise mechanism(s) by which this variant
modiﬁes CAD risk remains uncertain.
A notable ﬁnding was the association with CAD of
common variants located in the SCARB1 gene. Asso-
ciation of variants at the SCARB1 locus with CAD was
also reported by the CARDIoGRAMplusC4D con-
sortium, but this did not reach genome-wide signiﬁ-
cance (1). The gene encodes the canonical receptor,
SR-BI, responsible for HDL cholesteryl ester uptake
in hepatocytes and steroidogenic cells (33). Genetic
modulation of SR-BI levels in mice is associated with
marked changes in plasma HDL cholesterol (34).
Consistent with this, a rare loss of function variant in
which leucine replaces proline 376 (P376L) in SCARB1
was recently identiﬁed through sequencing of in-
dividuals with high plasma HDL cholesterol (35).
Interestingly, despite having higher plasma HDL,
346L carriers had an increased risk of CAD, suggesting
that the association of variation at this locus on CAD
is not driven primarily through plasma HDL (35).
Indeed, there is only a nominal association of the lead
CAD variant at this locus (rs11057830) with plasma
HDL cholesterol (Online Table 6). The variant is also
modestly associated with plasma LDL cholesterol and
serum triglycerides (Table 2). All 3 of these lipid as-
sociations are directionally consistent with epidemi-
ological evidence linking them to CAD risk and could,
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834in combination, explain the association of the locus
with CAD. However, the lead variant is more strongly
associated with Lp-PLA2 activity and mass (Table 3),
which could provide an alternative explanation for its
association with CAD. Irrespective of the mechanism,
our ﬁndings, when combined with those of Zanoni
et al. (35), suggest that modulating SR-B1 may be
therapeutically beneﬁcial.
After adjusting for multiple testing, we found
that slightly more than one-third of the CAD loci
showed an association with traditional cardiovas-
cular risk factors. Although the vast majority of
associations were in the direction consistent with
the epidemiological association of these risk factors
with CAD, as noted in the previous text with
respect to loci affecting the HDL cholesterol level,
this should not be interpreted as implying that
these loci affect CAD risk through an effect on the
speciﬁc risk factor. Indeed, for variants available on
the array with a known genome-wide association
with these risk factors, we found a poor correlation
between the magnitudes of their effect of the risk
factor and their association with CAD in our dataset
except for LDL cholesterol (Online Figure 4).
Nonetheless, formal causal inference analyses, using
Mendelian randomization, have implicated LDL
cholesterol, triglyceride-rich lipoproteins, blood
pressure, type 2 diabetes, and BMI as causally
involved in CAD (36).
Almost one-half of the CAD loci showed a strong or
suggestive association with other diseases or traits
with, in many cases, the identical variant being the
lead variant reported for the association with these
other conditions (Table 3). Some of the associations
with other traits—for example, coronary calciﬁcation
(3q22, 6p24, 9p21, 13q34, and 15q25) or carotid
intima-media thickness (4q31 and 19q13)—are not
surprising, as these traits are known to be correlated
with CAD. Others, such as risk of stroke (7p21 and
9p21), might reﬂect a shared etiology. However, the
mechanism(s) behind most of the observed pleiot-
ropy is not clear, although the ﬁndings could provide
clues as to how the locus may affect CAD risk. As an
example, 5 loci (12q24, 1p13, 6q25, 11q23, and 19q13)
show strong associations with plasma activity and/or
mass of Lp-PLA2. Lp-PLA2 is expressed in athero-
sclerotic plaques where studies have suggested a role
in the production of proinﬂammatory and pro-
apoptotic mediators, primarily through interaction
with oxidized LDL (37,38). A meta-analysis of pro-
spective studies showed an independent and
continuous relationship of plasma Lp-PLA2 with CAD
risk (39). However, it should be noted that Mendelian
randomization analyses have not supported a causalrole of secreted Lp-PLA2 in coronary heart disease
(40), and phase III trials of darapladib, an Lp-PLA2
inhibitor, have shown no beneﬁt in patients with
stable coronary heart disease (41) or acute coronary
syndromes (42) when added to conventional treat-
ments including statins.
Chronic inﬂammation plays a key role in both the
pathogenesis of CAD and of inﬂammatory bowel dis-
ease. It is therefore interesting to note the association
of the same locus at 15q22 with CAD as well as Crohn’s
disease and ulcerative colitis (Table 3). Association of
this locus with CAD at genome-wide signiﬁcance was
recently reported by the CARDIoGRAMplusC4D con-
sortium (2) with the lead SNP (rs56062135) showing
strong linkage disequilibrium (r2 ¼ 0.9) with the lead
SNP (rs17293632) associated with inﬂammatory bowel
disease. Both rs56062135 and rs17293632 lie in a re-
gion of w30 kb within the initial introns of the SMAD
family member 3 gene (SMAD3), a signal transducer in
the transforming growth factor–beta pathway.
Indeed, rs17293632 was included on the exome array
because of its known association with Crohn’s disease
and showed a signiﬁcant association with CAD in our
combined dataset (p ¼ 1.78  108). Farh et al. (43)
interrogated ChIP-seq data from ENCODE and found
allele-speciﬁc binding of the AP-1 transcription factor
to the major (C) allele in heterozygous cell lines and
suggested that the T allele of rs17293632 increases risk
of Crohn’s disease by disrupting AP-1 regulation of
SMAD3 expression. Interestingly, the direction of ef-
fect on CAD risk observed for this variant was in the
opposite direction to that for inﬂammatory disorders,
with the C allele being the risk allele. Recent analysis
of this variant in arterial smooth muscle cells
conﬁrmed that the CAD risk allele preserves AP-1
transcription factor binding and increases expres-
sion of SMAD3 (44). Further investigation of the
discordant effects of SMAD3 may shed light on the
mechanisms of both diseases.
STUDY LIMITATIONS. First, in our discovery study,
we were only able to interrogate common variants
associated with other diseases and traits that were
known at the time of the creation of the exome array
in late 2011 and, thus, included on the array.
Conversely, our interrogation for pleiotropic associ-
ations of the new and known CAD has used the latest
data available in the GWAS catalogs and other sour-
ces. Second, the common variants tested in our study
conferred statistically robust yet quantitatively
modest effects on both CAD and potentially related
traits. Thus, we may have missed associations with
other traits. However, if such traits were considered
as intermediary steps in the etiology of CAD,
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Novel genetic
loci inﬂuence risk of coronary artery disease, but only one-third
are associated with conventional cardiovascular risk factors,
whereas at least one-half of the loci are associated with other
diseases or traits (pleiotropy).
TRANSLATIONAL OUTLOOK: Future studies should investi-
gate the mechanisms that relate the observed pleiotropy to the
pathogenesis of atherosclerosis and ischemic events.
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835exploration of our large GWAS sample sets and
respective GWAS catalogs should have detected
relevant associations. Third, our discovery analysis is
largely on the basis of subjects with Western-
European ancestry, and any association with CAD of
the new loci in other populations needs further
evaluation. Finally, although we used relatively
stringent criteria (minimal r2 > 0.8 between the CAD
SNP and the lead variant associated with the other
disease/trait), the limited content of the exome array
and the information available in the GWAS catalogs
meant that we could not examine the extent of
overlap in the loci in detail.
CONCLUSIONS
Through an analysis of selected variants associated
with other disease traits, we reported the discovery of
6 further loci associated with CAD. Furthermore, in
the most comprehensive analysis to date, we showed
that several of the new and previously established
loci demonstrated substantial pleiotropy, which may
help our understanding of the mechanisms by which
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